我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
0
0 进行中
药物批准
批准总数
监管机构
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无批准数据
- The phase 2 LenCabo trial showed lenvatinib plus everolimus led to significantly greater reductions in BMI, skeletal muscle mass index, and subcutaneous adiposity at 4 months versus cabozantinib in metastatic ccRCC. - Dr. María Teresa Bourlon emphasized that this catabolic signal raises concerns for older, frail, or weight-compromised patients, potentially impacting quality of life and dose delivery. - Quality-of-life comparison at day 60 was inconclusive due to only 38 of 86 patients completing both assessments, limiting interpretability. - Clinicians are urged to carefully evaluate baseline patient fitness and body composition when considering lenvatinib/everolimus in this setting.
